UY33119A - Método de tratamiento de fibrilación atrial - Google Patents

Método de tratamiento de fibrilación atrial

Info

Publication number
UY33119A
UY33119A UY33119A UY33119A UY33119A UY 33119 A UY33119 A UY 33119A UY 33119 A UY33119 A UY 33119A UY 33119 A UY33119 A UY 33119A UY 33119 A UY33119 A UY 33119A
Authority
UY
Uruguay
Prior art keywords
treatment method
atrial fibrilation
fibrilation
atrial
treatment
Prior art date
Application number
UY33119A
Other languages
English (en)
Spanish (es)
Inventor
Charles Antzelevitch
Luiz Belardinelli
Alexander Burashnikov
John Shryock
Dewan Zeng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY33119A publication Critical patent/UY33119A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
UY33119A 2009-12-21 2010-12-20 Método de tratamiento de fibrilación atrial UY33119A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21

Publications (1)

Publication Number Publication Date
UY33119A true UY33119A (es) 2011-07-29

Family

ID=43736345

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33119A UY33119A (es) 2009-12-21 2010-12-20 Método de tratamiento de fibrilación atrial

Country Status (37)

Country Link
US (3) US8513254B2 (xx)
EP (2) EP2749282B1 (xx)
JP (2) JP5723889B2 (xx)
KR (2) KR20160108611A (xx)
CN (3) CN102665713B (xx)
AP (1) AP3536A (xx)
AR (1) AR079552A1 (xx)
AU (1) AU2010339753B2 (xx)
BR (1) BR112012015499A2 (xx)
CA (1) CA2784028C (xx)
CL (1) CL2012001597A1 (xx)
CR (1) CR20120353A (xx)
CY (1) CY1116511T1 (xx)
DK (1) DK2515900T3 (xx)
EA (2) EA025445B1 (xx)
EC (1) ECSP12012004A (xx)
ES (2) ES2646603T3 (xx)
HK (1) HK1170675A1 (xx)
HR (1) HRP20150644T1 (xx)
HU (1) HUE026916T2 (xx)
IL (1) IL220152A (xx)
ME (1) ME02179B (xx)
MX (2) MX2012007052A (xx)
NO (1) NO2749282T3 (xx)
NZ (2) NZ627181A (xx)
PE (1) PE20121520A1 (xx)
PL (2) PL2515900T3 (xx)
PT (2) PT2515900E (xx)
RS (1) RS54118B1 (xx)
SG (3) SG10201408528RA (xx)
SI (2) SI2749282T1 (xx)
SM (1) SMT201500171B (xx)
TW (1) TWI508726B (xx)
UA (1) UA109887C2 (xx)
UY (1) UY33119A (xx)
WO (1) WO2011084733A1 (xx)
ZA (1) ZA201204608B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011530A (es) 2002-05-21 2005-08-15 Cv Therapeutics Inc Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes.
CN102725290B (zh) 2009-07-27 2016-03-09 吉利德科学股份有限公司 作为离子通道调节剂的稠合杂环化合物
CA3068441C (en) 2009-07-29 2024-01-09 Icu Medical, Inc. Fluid transfer devices and methods of use
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
PT2588197E (pt) 2010-07-02 2015-02-09 Gilead Sciences Inc Compostos heterocíclicos fundidos como moduladores do canal de iões
CN105693645B (zh) 2011-05-10 2018-10-09 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
NO3175985T3 (xx) 2011-07-01 2018-04-28
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
WO2013112932A1 (en) * 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US20140364417A1 (en) * 2013-05-03 2014-12-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
MX2016001303A (es) * 2013-08-02 2016-04-07 Gilead Sciences Inc Composiciones farmaceuticas de ranolazina y dronedarona.
EP3068440B1 (en) 2013-11-15 2020-01-08 Northwestern University Inhibition of oxidative stress in atrial fibrillation
EP3083608B1 (en) 2013-12-19 2018-07-18 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
EP3423057A1 (en) 2016-03-04 2019-01-09 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
AU2020212054A1 (en) * 2019-01-24 2021-08-26 Northwestern University Gene therapy treatment of atrial fibrillation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
NZ247044A (en) 1989-06-23 1997-04-24 Syntex Usa Inc Substituted For Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU2001278045B2 (en) * 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
DE60117857D1 (de) 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
US20050065208A1 (en) * 2001-07-20 2005-03-24 Bodo Brandts Benzofuranes and their use in the treatment of atrial fibrillation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
US20060177502A1 (en) 2005-01-06 2006-08-10 Srikonda Sastry Sustained release pharmaceutical formulations
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
WO2008118552A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
EP2337559A2 (en) 2008-09-04 2011-06-29 Gilead Sciences, Inc. Method of treating atrial fibrillation

Also Published As

Publication number Publication date
DK2515900T3 (en) 2015-07-27
KR20160108611A (ko) 2016-09-19
US20140323493A1 (en) 2014-10-30
JP2015057449A (ja) 2015-03-26
NO2749282T3 (xx) 2018-01-06
CA2784028A1 (en) 2011-07-14
WO2011084733A1 (en) 2011-07-14
CL2012001597A1 (es) 2013-06-28
PE20121520A1 (es) 2012-11-26
ES2646603T3 (es) 2017-12-14
ZA201204608B (en) 2013-02-27
EP2515900A1 (en) 2012-10-31
HK1170675A1 (en) 2013-03-08
UA109887C2 (uk) 2015-10-26
EA201290451A1 (ru) 2013-01-30
AP2012006331A0 (en) 2012-06-30
PL2515900T3 (pl) 2015-10-30
CY1116511T1 (el) 2017-03-15
US9056108B2 (en) 2015-06-16
KR20120107995A (ko) 2012-10-04
PL2749282T3 (pl) 2018-01-31
CA2784028C (en) 2016-08-23
ES2540093T3 (es) 2015-07-08
US20110183990A1 (en) 2011-07-28
HUE026916T2 (en) 2016-08-29
TW201136586A (en) 2011-11-01
IL220152A0 (en) 2012-07-31
NZ600718A (en) 2014-08-29
MX2012007052A (es) 2012-07-30
US8754087B2 (en) 2014-06-17
US8513254B2 (en) 2013-08-20
TWI508726B (zh) 2015-11-21
CN102665713B (zh) 2015-02-18
MX344329B (es) 2016-12-13
PT2749282T (pt) 2017-11-15
EP2515900B1 (en) 2015-04-29
BR112012015499A2 (pt) 2016-05-03
AR079552A1 (es) 2012-02-01
RS54118B1 (en) 2015-12-31
IL220152A (en) 2016-11-30
CN102665713A (zh) 2012-09-12
CN104688739A (zh) 2015-06-10
ECSP12012004A (es) 2012-08-31
EP2749282B1 (en) 2017-08-09
AU2010339753B2 (en) 2015-01-22
US20130317038A1 (en) 2013-11-28
SG10201408528RA (en) 2015-04-29
CN104147010A (zh) 2014-11-19
EA201691336A1 (ru) 2017-05-31
SG181541A1 (en) 2012-07-30
EA025445B1 (ru) 2016-12-30
AP3536A (en) 2016-01-13
JP2013515007A (ja) 2013-05-02
SMT201500171B (it) 2015-09-07
NZ627181A (en) 2016-02-26
PT2515900E (pt) 2015-07-30
CR20120353A (es) 2014-10-07
JP5723889B2 (ja) 2015-05-27
HRP20150644T1 (hr) 2015-07-31
AU2010339753A1 (en) 2012-07-12
EP2749282A1 (en) 2014-07-02
SG10201710751TA (en) 2018-02-27
SI2749282T1 (sl) 2017-12-29
SI2515900T1 (sl) 2015-07-31
ME02179B (me) 2015-10-20

Similar Documents

Publication Publication Date Title
UY33119A (es) Método de tratamiento de fibrilación atrial
BRPI0910854A2 (pt) métodos de tratamento
BRPI0910259A2 (pt) métodos de tratamento de inflamação
BR112012004707A2 (pt) método
BR112012000624A2 (pt) método
FI20090389A0 (fi) Menetelmä
BRPI0917575A2 (pt) métodos de tratamento de talassemia
BR112013013584A2 (pt) endoscópio, e, método
IT1395537B1 (it) Metodo di monitoraggio
DK2646208T3 (da) Miljøvenlig træbehandlingsprocess
BR112012005117A2 (pt) método de tratamento de esofagite eosinofílica
BR112013012485A2 (pt) método de tratamento com inibidor braf
BRPI1012526A2 (pt) método
BR112014031224A2 (pt) método de descelularização de osso
BR112013016491A2 (pt) método para tratamento de têxtil
BRPI1010705A2 (pt) método
BRPI0919127A2 (pt) métodos para tratamento de água
DK2330887T3 (da) Behandlingsindretning
BR112014016108A2 (pt) método de tratamento de perda óssea alvelar
IL220594A0 (en) Treatment method
IL217492A0 (en) Treatment method
BR112013022820A2 (pt) método de tratamento
BRPI1012532A2 (pt) método
BR112013023142A2 (pt) método de tratamento de cabelos
BRPI1007543A2 (pt) tratamento de psoríase

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190225